![]() Each of Quidel and Ortho commenced mailing copies of the definitive joint proxy statement/prospectus to stockholders of Quidel and Ortho, respectively, on or about April 11, 2022. The registration statement, as amended, was declared effective by the Commission on April 11, 2022. 333-262434) with the Securities and Exchange Commission (the “Commission”) that contains a definitive joint proxy statement/prospectus and other relevant documents concerning the proposed transaction. Where You Can Find Additional InformationIn connection with the proposed business combination transaction among Quidel, Ortho and Topco, Topco has filed a registration statement on Form S-4 (File No. The company is powered by Ortho Care®, an award-winning, holistic service and support program that ensures best-in-class technical, field and remote service and inventory support to laboratories in more than 130 countries and territories around the globe.įor more information, visit Ortho’s website or social media channels: LinkedIn, Twitter, Facebook and YouTube. Food and Drug Administration-authorized high-volume antibody and antigen tests for COVID-19, Ortho has been a pioneering leader in the IVD space for over 80 years. Ortho's customized solutions enhance clinical outcomes, improve efficiency, overcome lab staffing challenges and reduce costs.įrom launching the first product to determine Rh+ or Rh- blood type, developing the world’s first tests for the detection of antibodies against HIV and hepatitis C, introducing patented dry-slide technology and marketing the first U.S. Because Every Test Is A Life™, Ortho provides hospitals, hospital networks, clinical laboratories and blood banks around the world with innovative technology and tools to ensure test results are fast, accurate, and reliable. More than 800,000 patients across the world are affected by Ortho’s tests each day. Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) is one of the world’s larger pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care. ![]() View our story told by our people at About Ortho Clinical Holdings, Inc. ![]() For more information about Quidel, visit. Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. Under trusted brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Quidel stockholders will receive one share of QuidelOrtho common stock for each share of Quidel common stock.Ībout Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. ![]() Under the terms of the agreement governing the transaction, Ortho shareholders will receive $7.14 in cash and 0.1055 shares of QuidelOrtho common stock for each Ortho common share. QuidelOrtho will be the successor to Quidel for purposes of the combined company’s Nasdaq listing. Shares of common stock of QuidelOrtho are expected to begin trading on the Nasdaq Global Select Market at the open of business on under the symbol “QDEL.” Shares of Quidel and Ortho will cease trading after the market close on May 26, 2022, and following the closing, Ortho will no longer be listed on Nasdaq. Following the effectiveness of a merger involving Quidel that will take place after the effectiveness of the Ortho Scheme Order, Quidel will also become a wholly owned subsidiary of Topco, and Topco will be renamed QuidelOrtho Corporation. The order will become effective once the Ortho Scheme Order is duly filed with the Registrar of Companies in England and Wales, which is expected to occur on May 27, 2022, at which point Ortho will become a wholly owned subsidiary of Coronado Topco, Inc. On May 26, 2022, the High Court of Justice of England and Wales issued an order under Part 26 of the UK Companies Act sanctioning the scheme of arrangement to be undertaken by Ortho in connection with the business combinations (the “Ortho Scheme Order”). SAN DIEGO, (GLOBE NEWSWIRE) - Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics Holdings plc (“Ortho”), one of the world’s larger pure-play in vitro diagnostics companies, announced today that the closing of the previously announced Ortho transaction is expected to occur on May 27, 2022.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |